These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30659762)

  • 1. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
    Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
    Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y; Sakurai J; Yoshida S; Kikuchi T; Mitsuhashi T; Miyake T; Fujimura T; Abe R; Fujikawa H; Boki H; Suga H; Shibata S; Miyagaki T; Shimauchi T; Kiyohara E; Kawakami Y; Morizane S
    J Dermatol; 2024 Aug; 51(8):1037-1049. PubMed ID: 38874430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.
    Zhang C; Chairatchaneeboon M; Haun P; Landsburg D; Kim EJ
    JAMA Dermatol; 2018 Jan; 154(1):109-110. PubMed ID: 29167875
    [No Abstract]   [Full Text] [Related]  

  • 9. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
    Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
    J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
    Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
    J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
    [No Abstract]   [Full Text] [Related]  

  • 12. [Management of mycosis fungoide : focus on brentuximab vedotin].
    Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RF - Brentuximab as Treatment for CD30
    Morgado-Carrasco D; Combalia A; Estrach Panella T
    Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
    [No Abstract]   [Full Text] [Related]  

  • 15. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
    Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
    J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response to brentuximab vedotin in refractory nontransformed CD30
    Mahévas T; Ram-Wolff C; Battistella M; Pennamen MDV; Rivet J; Brice P; Bagot M
    Br J Dermatol; 2019 Jun; 180(6):1517-1520. PubMed ID: 30269331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
    Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
    Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding.
    Buchely N; Al-Rohil RN; Aung PP; Jour G; Torres-Cabala C; Prieto VG; Ivan D
    J Cutan Pathol; 2018 May; ():. PubMed ID: 29806104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
    Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
    J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.